Latest Thyroid neoplasm Stories
REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics (Nasdaq: DCGN) today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer.
Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say.
In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.
WALTHAM, Mass., Oct. 21, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
MUM-OF-TWO Cath Mullinder was given financial support after cancer stopped her from working. Cath, who is an assistant social worker for Macmillan Cancer Support, was earlier this year diagnosed with thyroid cancer. Cath, of Wylam, was given radioactive iodine treatment at Newcastle General Hospital.
Participants of a Rehabilitation Institute of Chicago gala say movie reviewer Roger Ebert is an inspiration for surviving multiple bouts with cancer.
By Montone, Kathleen T Baloch, Zubair W; LiVolsi, Virginia A Context.-Hurthle cells are eosinophilic, follicular-derived cells that are associated with a variety of nonneoplastic and neoplastic thyroid lesions. The differential diagnosis of Hurthle cell lesions is quite broad.
Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK.
By Megan Williams, The Free Lance-Star, Fredericksburg, Va. Jul. 27--When Anita Kaissi found herself feeling constantly sluggish, she thought it was because she had just had a baby.